Presentation is loading. Please wait.

Presentation is loading. Please wait.

IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist  Rebecca E. Slager, PhD, MS,

Published byGwenda Bennett Modified over 6 years ago

Similar presentations

Presentation on theme: "IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist  Rebecca E. Slager, PhD, MS,"— Presentation transcript:

1 IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist  Rebecca E. Slager, PhD, MS, Babatunde A. Otulana, MD, Gregory A. Hawkins, PhD, Yu Ping Yen, PhD, Stephen P. Peters, MD, PhD, Sally E. Wenzel, MD, Deborah A. Meyers, PhD, Eugene R. Bleecker, MD  Journal of Allergy and Clinical Immunology  Volume 130, Issue 2, Pages e4 (August 2012) DOI: /j.jaci Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Exacerbations by treatment assignment stratified by IL4RA SNP genotype. There was a significant dose-response trend for treatment response to exacerbations in subjects homozygous for the rs8832GG genotype (A) and the GG genotype in the correlated SNP rs (B). Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 IL4RA variants associated with exacerbations. Seven IL4RA SNPs were significantly associated with asthma exacerbations by genotype in participants randomized to 3- and 10-mg doses of pitrakinra. The dashed line indicates overall exacerbation frequency (19.7%) in genotyped non-Hispanic white subjects. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Kaplan-Meier plot for time to exacerbation by treatment assignment for subjects with the rs8832GG genotype. On study day 28, LABAs were withdrawn, and inhaled corticosteroids were stepped down on study days 42 and 56 and stopped completely on day 70. There was a significant difference in time to exacerbation by survival time analysis for subjects with the rs8832GG genotype randomized to 10 mg of pitrakinra compared with placebo. P values are from log-rank tests. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 IL4RA polymorphisms predict change in nighttime awakenings caused by asthma. There was a significant dose-response trend for change in nighttime awakenings by treatment assignment (placebo/1 mg/3 mg/10 mg) observed for subjects with the common rs8832GG genotype (A) and participants with the common rs CC genotype (B). There was no significant trend for participants with the minor allele in these SNPs. CFB, Change from baseline. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig E1 Map of IL4RA variants genotyped in this study and the linkage disequilibrium (r2) plot (generated in Haploview version 4.2) for genotyped non-Hispanic white subjects. Significant pharmacogenetic associations with asthma exacerbations are noted. Journal of Allergy and Clinical Immunology  , e4DOI: ( /j.jaci ) Copyright © 2012 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti–IL-4 receptor α antagonist  Rebecca E. Slager, PhD, MS,"

Similar presentations

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.

Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered- dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder.
Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients  Xingnan Li, PhD, MS, Gregory A. Hawkins,

Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients  Xingnan Li, PhD, MS, Gregory A. Hawkins,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial 

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial 
Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes  Annette T. Hastie, PhD, Wendy C. Moore,

Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes  Annette T. Hastie, PhD, Wendy C. Moore,
Russell S. Traister, MD, PhD, Crystal E. Uvalle, BS, Gregory A

Russell S. Traister, MD, PhD, Crystal E. Uvalle, BS, Gregory A
Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients  Xingnan Li, PhD, MS, Gregory A. Hawkins,

Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients  Xingnan Li, PhD, MS, Gregory A. Hawkins,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 

Stephen J. Fowler, MD, Gaël Tavernier, PhD, Robert Niven, MD 
David A. Khan, MD  Journal of Allergy and Clinical Immunology 

David A. Khan, MD  Journal of Allergy and Clinical Immunology 
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,

Probiotics during the first 7 years of life: A cumulative risk reduction of eczema in a randomized, placebo-controlled trial  Marko Kalliomäki, MD, PhD,
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
Association between (CCTTT)n repeat polymorphism in NOS2 promoter and asthma exacerbations  Keita Hirai, PhD, Toshihiro Shirai, MD, PhD, Masayuki Suzuki,

Association between (CCTTT)n repeat polymorphism in NOS2 promoter and asthma exacerbations  Keita Hirai, PhD, Toshihiro Shirai, MD, PhD, Masayuki Suzuki,
Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40  Jose L. Gomez, MD, MS, Gina M. Crisafi,

Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40  Jose L. Gomez, MD, MS, Gina M. Crisafi,
Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J

Lieuwe D. Bos, MSc, PhD, Peter J. Sterk, MD, PhD, Stephen J
Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point  Emma C.Y. Hilton, PhD, Paul G.

Pharmacodynamic modeling of cough responses to capsaicin inhalation calls into question the utility of the C5 end point  Emma C.Y. Hilton, PhD, Paul G.
Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients  William W. Busse, MD, Sally E. Wenzel, MD, Eli O. Meltzer,

Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients  William W. Busse, MD, Sally E. Wenzel, MD, Eli O. Meltzer,
Genetic risk factors for decreased bone mineral accretion in children with asthma receiving multiple oral corticosteroid bursts  Heung-Woo Park, MD, PhD,

Genetic risk factors for decreased bone mineral accretion in children with asthma receiving multiple oral corticosteroid bursts  Heung-Woo Park, MD, PhD,

Similar presentations

Ads by Google